Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Stereotactic body radiotherapy in the treatment of Pancreatic Adenocarcinoma in elderly patients

Kim, CH and Ling, DC and Wegner, RE and Flickinger, JC and Heron, DE and Zeh, H and Moser, AJ and Burton, SA (2013) Stereotactic body radiotherapy in the treatment of Pancreatic Adenocarcinoma in elderly patients. Radiation Oncology, 8 (1).

Published Version
Available under License : See the attached license file.

Download (963kB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)


Background: Treatment of pancreatic adenocarcinoma in the elderly is often complicated by comorbidities that preclude surgery, chemotherapy and/or conventional external beam radiation therapy (EBRT). Stereotactic body radiotherapy (SBRT) has thus garnered interest in this setting.Methods: A retrospective review of 26 patients of age ≥ 80 with pancreatic adenocarcinoma treated with definitive SBRT+/-chemotherapy from 2007-2011 was performed. Twenty-seven percent of patients were stage I, 38% were stage II, 27% were stage III and 8% were stage IV. Patients most commonly received 24 Gy/1 fraction or 30-36 Gy/3 fractions. Kaplan-Meier was used to estimate overall survival (OS), local control (LC), cause specific survival (CSS) and freedom-from-metastatic disease (FFMD).Results: The median age was 86 (range 80-91), and median follow-up was 11.6 months (3.5-24.6). The median planning target volume was 21.48 cm3 (6.1-85.09). Median OS was 7.6 months with 6/12 month OS rates of 65.4%/34.6%, respectively. Median LC was 11.5 months, 6-month and 12-month actuarial LC rates were 60.1% and 41.2%, respectively. There were no independent predictors for LC, but there was a trend for improved LC with prescription dose greater than 20 Gy (p = 0.063). Median CSS was 6.3 months, and 6-month and 12-month actuarial CSS were 53.8% and 23.1%, respectively. Median FFMD was 8.4 months, and 6-month and 12-month actuarial rates were 62.0% and 41.4%, respectively. Nine patients (47%) had local failures, 11 (58%) had distant metastasis, and 7 (37%) had both. There were no acute or late grade 3+ toxicities.Conclusions: Definitive SBRT is feasible, safe and effective in elderly patients who have unresectable disease, have comorbidities precluding surgery or decline surgery. © 2013 Kim et al.; licensee BioMed Central Ltd.


Social Networking:
Share |


Item Type: Article
Status: Published
CreatorsEmailPitt UsernameORCID
Kim, CH
Ling, DC
Wegner, RE
Flickinger, JCjflickin@pitt.eduJFLICKIN
Heron, DEdeh5@pitt.eduDEH5
Zeh, Hhjz1@pitt.eduHJZ1
Moser, AJ
Burton, SA
Centers: Other Centers, Institutes, Offices, or Units > Pittsburgh Cancer Institute
Date: 16 October 2013
Date Type: Publication
Journal or Publication Title: Radiation Oncology
Volume: 8
Number: 1
DOI or Unique Handle: 10.1186/1748-717x-8-240
Schools and Programs: School of Medicine > Radiation Oncology
School of Medicine > Surgery
Refereed: Yes
Date Deposited: 02 Dec 2016 16:09
Last Modified: 22 Jun 2021 15:55


Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item